← Evidence map

ArticleCardiovascular endocrinology & metabolism2025

BRIDGE-DS study: a multicenter, observational, retrospective analysis of dapagliflozin and sitagliptin combination on modifiable cardiovascular risk factors in T2DM patients with ASCVD or high cardiovascular risk.

Naveen Bhamri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

BRIDGE-DS study: a multicenter, observational, retrospective analysis of dapagliflozin and sitagliptin combination on modifiable cardiovascular risk factors in T2DM patients with ASCVD or high cardiovascular risk. | OpenQuestion